No es demencia, son las estatinas para el colesterol

La ubicuas estatinas que se recetan a tutiplén para reducir los niveles de colesterol no solo aumentan el riesgo de diabetes tipo 2, de disfunción eréctil, de daño renal, de osteoporosis, de dolores musculares o de párkinson, sino que también provocan deterioro cognitivo e incluso… una falsa demencia. Sí, la palabra es «provocan».

Y aunque aún es pronto para pecar de contundentes, sí «sabemos» que la enfermedad cardiovascular no es consecuencia de que comamos mucha grasa, lo que aumenta los niveles del colesterol, que se acumula taponando las arterias… sino una complejísima condición inflamatoria multifactorial que apenas comenzamos a comprender.


¿Quieres oír este capítulo? Suscríbete al podcast en ivoox

y escúchalo en Apple Podcasts, Amazon Music o Spotify Podcasts.

Referencias (por orden de aparición):

Morris, Z. S., Wooding, S., & Grant, J. (2011). The answer is 17 years, what is the question: Understanding time lags in translational research. Journal of the Royal Society of Medicine, 104(12), 510-520.

Wenner Moyer, M. (2010). It’s Not Dementia, It’s Your Heart Medication: Cholesterol Drugs and Memory. Scientific American.

Frantz, I. D., Jr, Dawson, E. A., Ashman, P. L., Gatewood, L. C., Bartsch, G. E., Kuba, K., & Brewer, E. R. (1989). Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis, 9(1), 129–135.

BIBLIOGRAFÍA RECOMENDADA: Teicholz, N. (2017). La grasa no es como la pintan: Mitos, historias y realidades del alimento que tu cuerpo necesita. Disponible en Amazon.

Harcombe, Z. (2010). The Obesity Epidemic: What caused it? How can we stop it? Disponible en Amazon.

Ramsden, C. E., …, Frantz, R. P., … & Hibbeln, J. R. (2016). Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ (Clinical research ed.), 353, i1246.

Begley, S. (2017). Records Found in Dusty Basement Undermine Decades of Dietary Advice. Scientific American.

Mann, G. V. (1977). Diet-Heart: End of an Era. New England Journal of Medicine, 297(12), 644-650.

Woodhill, J. M., … & Blacket, R. B. (1978). Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Advances in Experimental Medicine and Biology, 109.

Ramsden, C. E., …., & Hibbeln, J. R. (2013). Evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ, 346, e8707.

Aguilar-Ballester, M., … & González-Navarro, H. (2020). Impact of Cholesterol Metabolism in Immune Cell Function and Atherosclerosis. Nutrients, 12(7), 2021.

Zhang, J., & Liu, Q. (2015). Cholesterol metabolism and homeostasis in the brain. Protein & Cell, 6(4), 254-264.

Gofman, J. W., … & Strisower, B. (1950). Blood lipids and human atherosclerosis. Circulation, 2(2), 161-178.

Jones, H. B., Gofman, J. W., … & Nichols, A. V. (1951). Lipoproteins in atherosclerosis. The American Journal of Medicine, 11(3), 358-380.

Gofman, J. W., Tamplin, A., & Strisower, B. (1954). Relation of Fat and Caloric Intake to Atherosclerosis. Journal of the American Dietetic Association, 30(4), 317-326.

Noakes, T. (2020). Ancel Keys’ Cholesterol Con: Part 1.

Aronson, D., & Rayfield, E. J. (2002). How hyperglycemia promotes atherosclerosis: Molecular mechanisms. Cardiovascular Diabetology, 1(1), 1.

Hoogeveen, R. C., Gaubatz, J. W., Sun, W., Dodge, R. C., Crosby, J. R., … & Ballantyne, C. M. (2014). Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(5), 1069-1077.

Ivanova, E. A., … & Orekhov, A. N. (2017). Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, 1273042.

BIBLIOGRAFÍA RECOMENDADA: Kendrick, M. (2021). The Clot Thickens: The enduring mystery of heart disease. Disponible en Amazon.

Itabe, H., Obama, T., & Kato, R. (2011). The Dynamics of Oxidized LDL during Atherogenesis. Journal of Lipids, 2011, 418313.

Brown, M. S., & Goldstein, J. L. (1984). How LDL Receptors Influence Cholesterol and Atherosclerosis. Scientific American, 251(5), 58-69.

Brown MS, Goldstein JL. (1996).  Heart attacks: Gone with the Century? Science,272: 629.

Newman, J. (2013). Multiple Risk Factor Intervention Trial (MRFIT). En M. D. Gellman & J. R. Turner (Eds.), Encyclopedia of Behavioral Medicine (pp. 1273-1274). Springer.

Stamler, J., Wentworth, D., & Neaton, J. D. (1986). Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256(20), 2823-2828.

Goldstein, J. L., & Brown, M. S. (2015). A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 161(1), 161-172.

Diamond, D. M., & Ravnskov, U. (2015). How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Review of Clinical Pharmacology, 8(2), 201-210.

Mansi, I. A., … & Alvarez, C. A. (2021). Association of Statin Therapy Initiation With Diabetes Progression. JAMA Internal Medicine, 181(12), 1562-1574.

Bruckert, E., Giral, P., Heshmati, H. M., & Turpin, G. (1996). Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. Journal of Clinical Pharmacy and Therapeutics, 21(2), 89-94.

Acharya, T., … & Mansi, I. A. (2016). Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). The American Journal of Cardiology, 117(4), 647-655.

Leutner, M., … & Kautzky-Willer, A. (2019). Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Annals of the Rheumatic Diseases, 78(12), 1706-1711.

Mansi, I., … & Mortensen, E. M. (2013). Statins and Musculoskeletal Conditions, Arthropathies, and Injuries. JAMA Internal Medicine, 173(14), 1318-1326.

Liu, G., Sterling, N. W., Kong, L., Lewis, M. M., Mailman, R. B., Chen, H., Leslie, D., & Huang, X. (2017). Statins may facilitate Parkinson’s disease: Insight gained from a large, national claims database. Movement Disorders, 32(6), 913-917.

Padala, K. P., … & Potter, J. F. (2012). The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: A prospective withdrawal and rechallenge pilot study. The American Journal of Geriatric Pharmacotherapy, 10(5), 296-302.

West, R., Beeri, M. S., Schmeidler, J., Hannigan, C. M., Angelo, G., Grossman, H. T., Rosendorff, C., & Silverman, J. M. (2008). Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 16(9), 781-785.

Principales Datos del Sistema Nacional de Salud. (2021). Ministerio de Sanidad.

Demasi, M. (2018). Statin wars: Have we been misled about the evidence? A narrative review. British Journal of Sports Medicine, 52(14), 905-909.

Taubes, G. (2007). Good Calories, Bad Calories: Fats, Carbs, and the Controversial Science of Diet and Health. Disponible en Amazon.

Suleng, K. (2019). La mala fama de las estatinas, el fármaco que se receta contra el colesterol, analizada por expertos. El País.

Habib, A. R., Katz, M. H., & Redberg, R. F. (2022). Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm. JAMA Internal Medicine.

Podría interesarte